KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eli Lilly (LLY) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Eli Lilly (LLY) over the last 17 years, with Q3 2025 value amounting to $150.1 million.

  • Eli Lilly's Gains from Investment Securities fell 4541.82% to $150.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $670.2 million, marking a year-over-year decrease of 1419.79%. This contributed to the annual value of $677.3 million for FY2024, which is 732.07% down from last year.
  • Per Eli Lilly's latest filing, its Gains from Investment Securities stood at $150.1 million for Q3 2025, which was down 4541.82% from $171.2 million recorded in Q2 2025.
  • Over the past 5 years, Eli Lilly's Gains from Investment Securities peaked at $971.9 million during Q3 2023, and registered a low of -$643.1 million during Q2 2023.
  • Moreover, its 5-year median value for Gains from Investment Securities was $146.0 million (2023), whereas its average is $181.9 million.
  • As far as peak fluctuations go, Eli Lilly's Gains from Investment Securities soared by 53606.56% in 2021, and later crashed by 64500.0% in 2023.
  • Quarter analysis of 5 years shows Eli Lilly's Gains from Investment Securities stood at $927.2 million in 2021, then tumbled by 86.4% to $126.1 million in 2022, then surged by 103.01% to $256.0 million in 2023, then plummeted by 40.55% to $152.2 million in 2024, then fell by 1.38% to $150.1 million in 2025.
  • Its last three reported values are $150.1 million in Q3 2025, $171.2 million for Q2 2025, and $196.7 million during Q1 2025.